home / stock / virx / virx news


VIRX News and Press, Viracta Therapeutics Inc. From 05/31/22

Stock Information

Company Name: Viracta Therapeutics Inc.
Stock Symbol: VIRX
Market: NASDAQ
Website: viracta.com

Menu

VIRX VIRX Quote VIRX Short VIRX News VIRX Articles VIRX Message Board
Get VIRX Alerts

News, Short Squeeze, Breakout and More Instantly...

VIRX - SQZ Biotechnologies names Marshelle Smith Warren as chief medical officer

SQZ Biotechnologies (NYSE:SQZ) has appointed Marshelle Smith Warren as chief medical officer, effective June 1. She was previously CMO and SVP, R&D at Viracta Therapeutics (VIRX). She has also served as a senior advisor clinical research programs for investigational T cell therapies ...

VIRX - Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman

Former Worldwide Head of Licensing and Acquisition and Knowledge Management at Merck & Co., where he led the completion of more than150 business development transactions Former Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals Former Ve...

VIRX - Viracta Therapeutics to Present at Upcoming May Investor Conferences

Viracta Therapeutics to Present at Upcoming May Investor Conferences PR Newswire SAN DIEGO , May 11, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced ...

VIRX - Viracta Therapeutics GAAP EPS of -$0.28

Viracta Therapeutics press release (NASDAQ:VIRX): Q1 GAAP EPS of -$0.28. Cash balance of $92.2 million as of March 31, 2022; projected cash runway into mid-2024 For further details see: Viracta Therapeutics GAAP EPS of -$0.28

VIRX - Viracta Therapeutics Reports First Quarter 2022 Financial Results and Recent Updates

Viracta Therapeutics Reports First Quarter 2022 Financial Results and Recent Updates PR Newswire Continued global expansion of NAVAL-1, the pivotal trial of Nana-val for the treatment of Epstein-Barr virus-positive (EBV + ) lymphoma; update on the initial cohort(s)...

VIRX - Viracta Therapeutics to Host Key Opinion Leader Webinar on Nana-val for the Treatment of Advanced Epstein-Barr Virus-Positive Solid Tumors

Viracta Therapeutics to Host Key Opinion Leader Webinar on Nana-val for the Treatment of Advanced Epstein-Barr Virus-Positive Solid Tumors PR Newswire Virtual event to take place on Wednesday, April 27, 2022 , at 11:00 AM EDT SAN DIEGO , April...

VIRX - VIRX, ARQQ and GWGH among mid-day movers

Gainers: Casa Systems (CASA) +67%. CEL-SCI Corporation (CVM) +55%. Natus Medical (NTUS) +29%. Frequency Therapeutics (FREQ) +26%. GWG Holdings (GWGH) +20%. IMARA (IMRA) +19%. Iveda Solutions (IVDA) +18%. AgriFORCE (AGRI) +18%. Maris-Tech (MTEK) +17%. Tritium DCFC (DCFC) +12%. Losers...

VIRX - CTRM, VIRX and CYTO among mid-day movers

Gainers: Veru (VERU) +196%. Hoth Therapeutics (HOTH) +126%. Altamira Therapeutics (CYTO) +54%. Iveda Solutions (IVDA) +37%. VNET Group (VNET) +30%. SailPoint Technologies Holdings (SAIL) +29%. Castor Maritime (CTRM) +25%. Datto Holding (MSP) +21%. Axcella Health (AXLA) +16%. TScan Therapeutic...

VIRX - Viracta Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

Viracta Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference PR Newswire SAN DIEGO , April 7, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignanc...

VIRX - Viracta Therapeutics Announces New Employment Inducement Grant

Viracta Therapeutics Announces New Employment Inducement Grant PR Newswire SAN DIEGO , March 18, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that...

Previous 10 Next 10